澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

BOTANIX PHARMACEUTICALS LTD

0.021

+0.0015.00%

成交量：253.82萬

成交額：5.08萬

市值：5,742.06萬

市盈率：-0.45

高：0.021

開：0.020

低：0.019

收：0.020

52周最高：0.170

52周最低：0.018

股本：27.34億

流通股本：17.18億

量比：0.37

換手率：0.15%

股息：- -

股息率：- -

每股收益(TTM):-0.046

每股收益(LYR):-0.047

淨資產收益率：-121.11%

總資產收益率：-53.38%

市淨率：1.06

市盈率(LYR):-0.45

資料載入中...

總覽公司新聞資訊公告

Botanix Pharmaceuticals Ltd - Botanix獲得關於Sofdra®藥物活性成分的額外美國專利授權通知

皮拉馬爾製藥解決方案宣佈與Botanix合作，支持藥物原料開發

Botanix製藥與Piramal達成合作後者將啓動Sofdra活性成分溴化索夫溴銨的開發服務並擔任替代商業供應商

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/BOT.AU/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BOT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","market":"AU","secType":"STK","nameCN":"BOTANIX PHARMACEUTICALS LTD","latestPrice":0.021,"timestamp":1787638320000,"preClose":0.02,"halted":0,"volume":2538233,"delay":0,"changeRate":0.050000000000000044,"nameEN":"BOTANIX PHARMACEUTICALS LTD","floatShares":1717605114,"shares":2734312800,"eps":-0.046233,"marketStatus":"未開盤","change":0.001,"latestTime":"08-25 16:12:00 AEST","open":0.02,"high":0.021,"low":0.019,"amount":50755,"amplitude":0.1,"askPrice":0.021,"askSize":6277407,"bidPrice":0.02,"bidSize":2269565,"shortable":3,"etf":0,"ttmEps":-0.046233,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.02,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.373218,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"BOT.AU","preClose":0.02,"auctionPrice":0.021,"auctionVolume":236,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638200800}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"BOT.AU\",,,,,undefined,":{"symbol":"BOT.AU","floatShares":1717605114,"roa":"-53.38%","roe":"-121.11%","lyrEps":-0.046827,"volumeRatio":0.373218,"shares":2734312800,"dividePrice":0,"high":0.021,"amplitude":0.1,"preClose":0.02,"low":0.019,"week52Low":0.018,"pbRate":"1.06","psRate":"2.62","week52High":0.17,"institutionHeld":0,"latestPrice":0.021,"committee":-0.46892,"eps":-0.046233,"divideRate":0,"volume":2538233,"delay":0,"ttmEps":-0.046233,"open":0.02,"prevYearClose":0.135,"prevWeekClose":0.02,"prevMonthClose":0.019,"prevQuarterClose":0.019,"fiveDayClose":0.02,"twentyDayClose":0.021,"sixtyDayClose":0.024},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BOT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BOT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BOT.AU\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1196520251","title":"Botanix Pharmaceuticals Ltd - Botanix獲得關於Sofdra®藥物活性成分的額外美國專利授權通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1196520251","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196520251?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 07:16","pubTimestamp":1783898172,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Ltd宣布，公司已收到关于Sofdra®药物活性成分的额外美国专利授权通知。这一进展进一步巩固了公司在该关键治疗领域的知识产权保护，为Sofdra®的商业化前景提供了更坚实的法律基础。新专利的授权有望增强产品的市场独占性，并为公司未来的价值增长带来积极影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","BK7502","BOT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156030135","title":"皮拉馬爾製藥解決方案宣佈與Botanix合作，支持藥物原料開發","url":"https://stock-news.laohu8.com/highlight/detail?id=1156030135","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156030135?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 21:58","pubTimestamp":1779112695,"startTime":"0","endTime":"0","summary":"皮拉马尔制药有限公司旗下业务单元皮拉马尔制药解决方案宣布，已与Botanix Pharmaceuticals Ltd建立合作伙伴关系，旨在为其药物原料的开发工作提供支持。此项合作将整合双方的专业能力，共同推进相关药物开发项目的进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","BK7508","BOT.AU","BK7502"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194932028","title":"Botanix製藥與Piramal達成合作 後者將啓動Sofdra活性成分溴化索夫溴銨的開發服務並擔任替代商業供應商","url":"https://stock-news.laohu8.com/highlight/detail?id=1194932028","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194932028?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 06:53","pubTimestamp":1776293594,"startTime":"0","endTime":"0","summary":"Botanix Pharmaceuticals Limited  宣布与Piramal Pharma Solutions建立重要合作伙伴关系。根据协议，Piramal将正式启动溴化索夫溴铵的开发服务，该活性药物成分是Botanix旗下创新疗法Sofdra的核心成分。此次合作标志着Piramal将成为溴化索夫溴铵的替代商业供应商，为Botanix提供关键原料的供应链保障。作为专注于皮肤病创新疗法的研发企业，Botanix通过此次合作进一步优化了其供应链体系。双方案担的协同合作，将为Sofdra未来的市场推广奠定坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BOT.AU","BK7096","BK7502","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":3,"code":"91000000","status":"200"}]}}